Endocrine Abstracts

Accumulating facts show that incretin-modulating therapy could be beneficial in both glycemic control and nephroprotection in type 2 diabetes (DM2). Clinical evidence for nephroprotective potential of DPP-4 inhibitors is limited and predictive determinants are unknown. The study conducted with DM2 patients aimed to assess renal effects of vildagliptin addition and identify their clinical and laboratory predictors. The study enrolled 44 insulin-treated male and female type 2 di...

Background: Recent studies have demonstrated antioxidant and anti-inflammatory properties of metformin and vildagliptin, that could result in some positive effects on kidney function in diabetes. Indeed, in our previous study vildagliptin attenuated routine renal dysfunction markers in insulinopenic diabetic rats, however metformin didn’t improve it. In our current study we evaluated not only glomerular dysfunction marker (albuminuria), but also novel markers of proximal ...

Background: Presently, a great deal of attention is being paid to investigation of pleiotropic effects of oral antidiabetic drugs. Several recent animal studies have suggested that vildagliptin and metformin could play some positive role in preventing the evolvement of diabetic nephropathy.Aim: This pilot study, concerned with high-fat fed heminephrectomized streptozotocin (STZ)-induced diabetic rats, aimed to evaluate and compare the effects of metformi...

Non-genetic animal models of diabetic nephropathy (DN) are most commonly reproduced by using streptozotocin (STZ) which preferentially gets into β-cells via GLUT2 transporters. However, STZ administration results in nephrotoxic effects as well, due to expression of GLUT2 by renal tubular epithelial cells. We hypothesized that nicotinamide (NA), which is considered to attenuate the severity of STZ-induced β-cell damage, could also prevent tubular alteration. Starting ...